What this study looked at
Alpha-mannosidosis (AM) is a rare inherited lysosomal disorder, and long-term data are important for understanding how useful a treatment really is. This prospectively designed analysis brought together data from 33 patients — 14 adults and 19 children — from the clinical development programme for velmanase alfa, an enzyme replacement therapy, to assess its long-term effectiveness and safety.
Key takeaways
- Serum oligosaccharide levels fell significantly by 12 months and remained significantly reduced at the last observation.
- Patients showed a meaningful improvement on the 3-minute stair climb test that was maintained over time, with a more pronounced benefit in children.
- Improvements in these biochemical and functional measures were sustained for up to four years, with no adverse events leading to permanent discontinuation.
Why it matters
The results support velmanase alfa as an effective and well-tolerated long-term treatment for AM, and suggest that starting therapy in childhood may lead to better functional outcomes.
